OverviewSuggest Edit

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operation. The Company and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

TypePublic
Founded2002
HQHenderson, NV, US
Websitesppirx.com
Employee Ratings2.9
Overall CultureC+

Latest Updates

Employees (est.) (Dec 2019)146(-37%)
Job Openings7
Revenue (FY, 2020)$0
Share Price (May 2022)$0.8(+3%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Spectrum Pharmaceuticals

Joseph W. Turgeon

Joseph W. Turgeon

President and Chief Executive Officer, Director
William L. Ashton

William L. Ashton

Chairman of the Board
Kurt A. Gustafson

Kurt A. Gustafson

Executive Vice President and Chief Financial Officer
Francois J. Lebel

Francois J. Lebel

Executive Vice President and Chief Medical Officer
Keith M. McGahan

Keith M. McGahan

Executive Vice President, Chief Legal Officer and Corporate Secretary
Thomas J. Riga

Thomas J. Riga

Executive Vice President, Chief Operating Officer and Chief Commercial Officer
Show more

Spectrum Pharmaceuticals Office Locations

Spectrum Pharmaceuticals has offices in Henderson and Irvine
Henderson, NV, US (HQ)
11500 S Eastern Ave #240
Irvine, CA, US
157 Technology Dr
Show all (2)

Spectrum Pharmaceuticals Financials and Metrics

Spectrum Pharmaceuticals Revenue

USD

Net income (Q1, 2021)

(35.7m)

EBIT (Q1, 2021)

(33.7m)

Market capitalization (12-May-2022)

123.0m

Closing stock price (12-May-2022)

0.8

Cash (31-Mar-2021)

69.5m
Spectrum Pharmaceuticals's current market capitalization is $123 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

193.0m255.0m155.9m186.8m162.6m146.4m128.4m109.3m

Revenue growth, %

30%(27%)7%

Cost of goods sold

33.8m7.9m4.4m

Gross profit

159.1m138.6m124.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

45.4m51.0m59.9m68.7m69.0m29.3m33.2m42.4m40.1m46.9m48.0m38.6m45.0m28.6m43.9m33.9m33.4m29.1m34.3m36.4m30.5m24.2m25.3m

Cost of goods sold

8.1m8.8m8.7m11.6m11.2m1.3m2.2m2.2m2.1m2.1m

Gross profit

37.2m42.2m51.2m57.1m57.9m42.6m31.7m31.2m27.0m32.2m36.4m30.5m

Gross profit Margin, %

82%83%86%83%84%97%93%93%93%94%100%100%
USDQ2, 2011

Financial Leverage

2 x
Show all financial metrics

Spectrum Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

3

Phase II Trials Products

1

Phase III Trials Products

3
Show all operating metrics

Spectrum Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Spectrum Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Spectrum Pharmaceuticals Online and Social Media Presence

Embed Graph

Spectrum Pharmaceuticals Company Culture

  • Overall Culture

    C+

    76/100

  • CEO Rating

    D+

    65/100

  • Compensation

    C-

    63/100

Learn more on Comparably

Spectrum Pharmaceuticals News and Updates

Thinking about buying stock in Hoth Therapeutics, Spectrum Pharmaceuticals, Datto Holding, Bilibili, or Hycroft Mining?

NEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOTH, SPPI, MSP, BILI, and HYMC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in BlackBerry, VEON, Ultrapar Participacoes, Spectrum Pharmaceuticals, or ThredUp?

NEW YORK, March 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BB, VEON, UGP, SPPI, and TDUP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Did You Acquire (SPPI) Before December 27, 2018? Should Spectrum Pharmaceuticals Management be Held Accountable for Investors Losses? Contact Johnson Fistel

SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) against certain of its officers and directors.

Worldwide Lymphoma Treatment Industry to 2026 - Featuring Abbott Laboratories, Novartis and Spectrum Pharmaceuticals Among Others

Dublin, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The "Lymphoma Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global lymphoma treatment market grew at a CAGR of around 8% during 2015-2020. …

FINAL ALERT: Robbins Geller Rudman & Dowd LLP Announces that Spectrum Pharmaceuticals, Inc. Investors with Significant Losses Have Opportunity to Lead Class Action Lawsuit - SPPI

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”) have until this upcoming Monday, November 1, 2021 to …

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important November 1 Deadline in Securities Class Action – SPPI

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November 1, 2021 …
Show more

Spectrum Pharmaceuticals Blogs

Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference

HENDERSON, Nev. --(BUSINESS WIRE)--May 17, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference , to be held

Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Content Import Thu, 05/12/2022 - 16:00 Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update May 12, 2022 at 4:00 PM EDT …

Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer

HENDERSON, Nev. --(BUSINESS WIRE)--May 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022 . Ms.

Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update

HENDERSON, Nev. --(BUSINESS WIRE)--May 6, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors

HENDERSON, Nev. --(BUSINESS WIRE)--May 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim Content Import Mon, 04/11/2022 - 07:00 Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim April 11, 2022 at 7:00 AM EDT General …
Show more

Spectrum Pharmaceuticals Frequently Asked Questions

  • When was Spectrum Pharmaceuticals founded?

    Spectrum Pharmaceuticals was founded in 2002.

  • Who are Spectrum Pharmaceuticals key executives?

    Spectrum Pharmaceuticals's key executives are Joseph W. Turgeon, William L. Ashton and Kurt A. Gustafson.

  • How many employees does Spectrum Pharmaceuticals have?

    Spectrum Pharmaceuticals has 146 employees.

  • Who are Spectrum Pharmaceuticals competitors?

    Competitors of Spectrum Pharmaceuticals include Jiangsu Hansoh Pharmaceutical Group, SK Biopharmaceuticals and Gracell.

  • Where is Spectrum Pharmaceuticals headquarters?

    Spectrum Pharmaceuticals headquarters is located at 11500 S Eastern Ave #240, Henderson.

  • Where are Spectrum Pharmaceuticals offices?

    Spectrum Pharmaceuticals has offices in Henderson and Irvine.

  • How many offices does Spectrum Pharmaceuticals have?

    Spectrum Pharmaceuticals has 2 offices.